Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab

OBJECTIVE: To compare drug survival on adalimumab, etanercept and infliximab in patients with rheumatoid arthritis (RA). METHODS: Patients with RA (n=9139; 76% women; mean age 56 years) starting their first tumour necrosis factor (TNF) inhibitor between 2003 and 2011 were identified in the Swedish B...

Descripción completa

Detalles Bibliográficos
Autores principales: Neovius, M, Arkema, E V, Olsson, H, Eriksson, J K, Kristensen, L E, Simard, J F, Askling, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316855/
https://www.ncbi.nlm.nih.gov/pubmed/24285495
http://dx.doi.org/10.1136/annrheumdis-2013-204128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316855/
https://www.ncbi.nlm.nih.gov/pubmed/24285495
http://dx.doi.org/10.1136/annrheumdis-2013-204128

Ejemplares similares